Inicio>>Signaling Pathways>> Microbiology & Virology>> HIV>>Bz-RS-iSer(3-Ph)-OMe

Bz-RS-iSer(3-Ph)-OMe

Catalog No.GC39739

Bz-RS-iSer(3-Ph)-OMe (compuesto 2), un derivado de Taxol, inhibe el ciclo de replicaciÓn del HSV con baja citotoxicidad, bloquea las divisiones mitÓticas de las células Vero, influye en el tamaÑo del tumor inducido por M-MSV y afecta la respuesta inmunitaria al inhibir la PHA inducida por la proliferaciÓn de linfocitos T.

Products are for research use only. Not for human use. We do not sell to patients.

Bz-RS-iSer(3-Ph)-OMe Chemical Structure

Cas No.: 32981-85-4

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
52,00 $
Disponible
100mg
46,00 $
Disponible
250mg
93,00 $
Disponible
500mg
158,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Bz-RS-iSer(3-Ph)-OMe (compound 2), a Taxol derivative, inhibits HSV replication cycle at low cytotoxicity, blocks mitotic divisions of Vero cells, influences M-MSV induced tumor size and affects immune response by inhibiting PHA-induced T lymphocyte proliferation[1].

[1]. Krawczyk E, et al. Cytotoxic, antiviral (in-vitro and in-vivo), immunomodulatory activity and influence on mitotic divisions of three taxol derivatives: 10-deacetyl-baccatin III, methyl (N-benzoyl-(2'R,3'S)-3'-phenylisoserinate) and N-benzoyl-(2'R,3'S)-3'-phenylisoserine. J Pharm Pharmacol. 2005;57(6):791‐797.

Reseñas

Review for Bz-RS-iSer(3-Ph)-OMe

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Bz-RS-iSer(3-Ph)-OMe

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.